A2δ1亚基阳性特异性PET探针的构建及在肝癌干细胞诊疗的研究

肝癌的发生、发展严重影响人民生活水平。降低肝癌高复发率、高致死率对改善肝癌预后尤为重要。本项目团队在肝癌干细胞研究取得突破性成果的基础上，本项目拟开发以钙离子通道α2δ1亚基为靶点，实时、在体分子水平探测肝癌干细胞的新型分子探针。本项目首先将通过对具有α2δ1特异性的1B50-1单抗进行修饰，而后利用医用回旋加速器制备新型核素64Cu并制备64Cu-NOTA-1B50-1 PET探针，而后利用64Cu-NOTA-1B50-1探针对肝癌干细胞进行定性、定量的检测，并进行肝癌干细胞的精确定位。并进一步通过该探针进行Micro-PET分析α2δ1受体肝癌干细胞与肿瘤恶性相关性。总而言之，本项目将通过开发基于α2δ1靶向的64Cu-NOTA-1B50-1分子探针，精确、无创的示踪肝癌干细胞，为靶向肿瘤干细胞的肝癌治疗提供依据和影像学基础。

Occurrence and metastasis of hepatic cellular cancer (HCC) have seriously affected people's living standards. Reduce the recurrence and mortality rate of HCC is virtual important to improve the prognosis of HCC. Based on this finding of calcium channelα2δ1 subunit recpetor in HCC, this project aims to develop α2δ1 targeting novel position emission tomography probe for the detection of liver cancer stem cell (LCSC). Firstly, using the HM-20 medical cyclotron to produce the new radio-uclide 64Cu, α2δ1 specific monoclonal antibody 1B50-1 will be modified and labeled to get the 64Cu-NOTA-1B50-1 PET probe. Then, we will use the 64Cu-NOTA-1B50-1 probe for the qualitative and quantitative detection of liver cancer stem cells, and the precise location of liver cancer stem cells. Furthermore, the Micro-PET was used to analyze the correlation between tumor cell proliferation and malignant tumor of α2δ1 receptor. In conclusion, this project will be developed through based on α2δ1 receptor targeting 64Cu-NOTA-1B50-1 antiodoby, for non invasive detects of liver cancer stem cell, and provides precison molecular imaging for LCSC treatment and therapy.